The launch of Wegovy, a new oral pill for weight loss, in the UAE has sparked significant interest and demand, particularly among first-time users. This is a notable shift from the traditional injectable form, which has been a common treatment for obesity. The availability of Wegovy in the UAE, priced between Dh779 and Dh1,610, has led to a surge in inquiries and prescriptions, with pharmacies reporting a 70-80% increase in demand. This trend is further supported by healthcare providers, with digital health platforms like DarDoc experiencing a high volume of patients on their waiting lists. The oral format is seen as more accessible and less intimidating than injections, making it appealing to a broader range of patients. The strong interest from first-time users suggests that the oral version of Wegovy is not only attracting those who have previously avoided weight-loss treatment but also those who prefer a non-injectable option. This shift in preference could be a significant development in the treatment of obesity, making it more widely accessible and patient-friendly. However, the question remains whether the supply of Wegovy will be sufficient to meet the growing demand. Pharmacies have been advised to secure stocks early due to the strong overall demand, and while the current supply is sufficient, the combination of a tablet format, growing awareness, and strong consumer interest could lead to a continued increase in demand. This development highlights the importance of ensuring a steady supply of such treatments to meet the rising demand and support the growing number of patients seeking weight-loss solutions.
